Convergent effects of a functional C3 variant on brain atrophy,demyelination,and cognitive impairment in multiple sclerosis

Abstract

Background:

Complement system activation products are present in areas of neuroinflammation, demyelination, and neurodegeneration in brains of patients with multiple sclerosis (MS). C3 is a central element in the activation of complement cascades. A common coding variant in the C3 gene (rs2230199, C3R102G) affects C3 activity.

Objectives:

To assess the effects of rs2230199 on MS severity using clinical, cognitive, and imaging measures.

Methods:

In total, 161 relapse-onset MS patients (Expanded Disability Status Scale (EDSS) ≤ 6) underwent physical assessments, cognitive tests (Paced Auditory Serial Addition Test (PASAT), Symbol Digit Modalities Test (SDMT), and California Verbal Learning Test (CVLT)), and magnetic resonance imaging (MRI). Lesion volumes were quantified semi-automatically. Voxel-wise analyses were performed to assess the effects of rs2230199 genotype on gray matter (GM) atrophy (n = 155), white matter (WM) fractional anisotropy (FA; n = 105), and WM magnetization transfer ratio (MTR; n = 90).

Results:

While rs2230199 minor-allele dosage (C3-102G) showed no significant effect on EDSS and Multiple Sclerosis Functional Composite (MSFC), it was associated with worse cognitive performance (p = 0.02), lower brain parenchymal fraction (p = 0.003), and higher lesion burden (p = 0.02). Moreover, voxel-wise analyses showed lower GM volume in subcortical structures and insula, and lower FA and MTR in several WM areas with higher copies of rs2230199 minor allele.

Conclusion:

C3-rs2230199 affects white and GM damage as well as cognitive impairment in MS patients. Our findings support a causal role for complement system activity in the pathophysiology of MS.

Keywords

Native immunity complement component 3 diffusion-weighted MRI magnetization transfer contrast imaging imaging genetics diffusion tensor imaging

Get full access to this article

View all access options for this article.

References

Sospedra

Martin

Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683–747.

Adams

Abdulla

Torres

et al . Periventricular lesions in multiple sclerosis: Their perivenous origin and relationship to granular ependymitis. Neuropathol Appl Neurobiol 1987; 13: 141–152.

Brink

Veerhuis

Breij

et al . The pathology of multiple sclerosis is location-dependent: No significant complement activation is detected in purely cortical lesions. J Neuropathol Exp Neurol 2005; 64: 147–155.

Barnett

Parratt

Cho

et al . Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol 2009; 65: 32–46.

Ingram

Loveless

Howell

et al . Complement activation in multiple sclerosis plaques: An immunohistochemical analysis. Acta Neuropathol Commun 2014; 2: 53.

Prineas

Kwon

Cho

et al . Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001; 50: 646–657.

Michailidou

Willems

Kooi

et al . Complement C1q-C3-associated synaptic changes in multiple sclerosis hippocampus. Ann Neurol 2015; 77: 1007–1026.

Ramaglia

Hughes

Donev

et al . C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proc Natl Acad Sci USA 2012; 109: 965–970.

Perry

Holmes

Microglial priming in neurodegenerative disease. Nat Rev Neurol 2014; 10: 217–224.

10.

Priya

Chew

Swaroop

Genetic studies of age-related macular degeneration: Lessons, challenges, and opportunities for disease management. Ophthalmology 2012; 119: 2526–2536.

11.

Heurich

Martínez-Barricarte

Francis

et al . Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci USA 2011; 108: 8761–8766.

12.

Arvilommi

Capacity of complement c3 phenotypes to bind on to mononuclear cells in man. Nature 1974; 251: 740–741.

13.

Enzinger

Barkhof

Ciccarelli

et al . Nonconventional MRI and microstructural cerebral changes in multiple sclerosis. Nat Rev Neurol 2015; 11: 676–686.

14.

Roostaei

Sadaghiani

Park

et al . Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis. Neurology 2016; 86: 410–417.

15.

Kurtzke

JF.

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.

16.

Eshaghi

Riyahi-Alam

Roostaei

et al . Validity and reliability of a Persian translation of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). Clin Neuropsychol 2012; 26: 975–984.

17.

Parmenter

Weinstock-Guttman

Garg

et al . Screening for cognitive impairment in multiple sclerosis using the symbol digit modalities test. Mult Scler 2007; 13: 52–57.

18.

Bazyar

Azarpira

Khatami

et al . The investigation of allele and genotype frequencies of human C3 (rs2230199) in south Iranian population. Mol Biol Rep 2012; 39: 8919–8924.

19.

Sahraian

Radü

EW.

MRI atlas of MS lesions. Berlin: Springer, 2007.

20.

Ashburner

Friston

KJ.

Voxel-based morphometry—the methods. Neuroimage 2000; 11: 805–821.

21.

Smith

Jenkinson

Johansen-Berg

et al . Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data. Neuroimage 2006; 31: 1487–1505.

22.

Lee

Chung

Lazar

et al . A study of diffusion tensor imaging by tissue-specific, smoothing-compensated voxel-based analysis. Neuroimage 2009; 44: 870–883.

23.

Smith

Nichols

TE.

Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 2009; 44: 83–98.

24.

Winkler

Webster

Vidaurre

et al . Multi-level block permutation. Neuroimage 2015; 123: 253–268.

25.

Hibar

Stein

Renteria

et al . Common genetic variants influence human subcortical brain structures. Nature 2015; 520: 224–229.

26.

Hibar

Adams

Jahanshad

et al . Novel genetic loci associated with hippocampal volume. Nat Commun 2017; 8: 13624.

27.

Stevens

Allen

Vazquez

et al . The classical complement cascade mediates CNS synapse elimination. Cell 2007; 131: 1164–1178.

28.

Schafer

Lehrman

Kautzman

et al . Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 2012; 74: 691–705.

29.

Shi

Colodner

Matousek

et al . Complement C3-deficient mice fail to display age-related hippocampal decline. J Neurosci 2015; 35: 13029–13042.

30.

Lui

Zhang

Makinson

et al . Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell 2016; 165: 921–935.

31.

Chung

Verghese

Chakraborty

et al . Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. Proc Natl Acad Sci USA 2016; 113: 10186–10191.

32.

Vercellino

Masera

Lorenzatti

et al . Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol 2009; 68: 489–502.

33.

Papadopoulos

Dukes

Patel

et al . Substantial archaeocortical atrophy and neuronal loss in multiple sclerosis. Brain Pathol 2009; 19: 238–253.

34.

Rodriguez

Nan

et al . A revised mechanism for the activation of complement C3 to C3b: A molecular explanation of a disease-associated polymorphism. J Biol Chem 2015; 290: 2334–2350.

35.

Nataf

Carroll

Wetsel

et al . Attenuation of experimental autoimmune demyelination in complement-deficient mice. J Immunol 2000; 165: 5867–5873.

36.

Aeinehband

Lindblom

Al Nimer

et al . Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis. PLoS ONE 2015; 10: e0122048.

37.

Ingram

Hakobyan

Hirst

et al . Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 2010; 133: 1602–1611.

38.

Hagens

van Berckel

Barkhof

Novel MRI and PET markers of neuroinflammation in multiple sclerosis. Curr Opin Neurol 2016; 29: 229–236.